BCRX Valuation Metrics
FCF$344.90M
FCF Growth Rate—
EPS Growth (CAGR)—
WACC10.00%
Biocryst Pharmaceuticals Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
Did you know?
BCRX's revenue grew at a 61.8% CAGR over the last 6 years.
Current Price
$9.19
+0.33%Profile
Valuation (TTM)
Market Cap$1.93B
P/E7.33
EV—
P/B—
Shares Out210.54M
P/Sales2.21
Revenue$874.84M
EV/EBITDA6.15
Biocryst Pharmaceuticals Inc (BCRX) Valuation
Fair Value Models
Graham Number, PEG-based, and Earnings-based models
View Fair Value →BCRX Valuation & Fair Value Analysis
Biocryst Pharmaceuticals Inc (BCRX) valuation analysis using multiple fair value methodologies. GoodMoat calculates a blended fair value target using discounted cash flow (DCF) analysis, the Graham Number, and earnings-based valuation models.
The price-to-earnings (P/E) ratio is 7.33. Price-to-sales ratio is 2.21. Enterprise value to EBITDA is 6.15. PEG ratio is -0.01.
GoodMoat's valuation models include the Graham Number (based on EPS and book value), an earnings-based model (discounted future EPS), and a PEG-adjusted valuation. The three models are averaged to produce a blended fair value estimate. Use these tools alongside the DCF calculator and reverse DCF to form a comprehensive view of Biocryst Pharmaceuticals Inc's intrinsic value.